Elizabeth Branham, APRN
Nurse Practitioner · Pikeville, KYNPI 1235777517
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 620 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,924, 2.3 times the $1,249 reported in 2021. Among nurse practitioner clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 620 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$718
- Novo Nordisk$665
- Novartis$626
- GSK$594
- Takeda Pharmaceuticals U.S.A., Inc.$569
- plus $5K from 30 others
What the payments were for
- Food & beverage$10,002100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 122 | $1,985 |
| AstraZeneca | 35 | $718 |
| Novo Nordisk | 39 | $665 |
| Novartis | 48 | $626 |
| GSK | 38 | $594 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $569 |
| Bayer | 33 | $542 |
| Amgen | 32 | $512 |
| Boehringer Ingelheim | 31 | $450 |
| Lilly USA, LLC | 31 | $434 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 23 | $413 |
| Pfizer | 23 | $331 |
| Grifols USA, LLC | 16 | $310 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $273 |
| Merck | 15 | $242 |
| Johnson & Johnson | 24 | $212 |
| Sanofi-aventis U.S. LLC | 10 | $177 |
| Daiichi Sankyo Inc. | 7 | $117 |
| Redhill Biopharma Inc. | 8 | $110 |
| Amarin Pharma, Inc. | 7 | $87 |
| Exact Sciences | 5 | $86 |
| Biohaven Pharmaceuticals, Inc. | 5 | $81 |
| Ardelyx, Inc. | 4 | $78 |
| Kowa Pharmaceuticals America, Inc. | 4 | $66 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $63 |
| Phathom Pharmaceuticals, Inc. | 3 | $53 |
| Verona Pharma, Inc. | 2 | $36 |
| Optinose US, Inc. | 2 | $31 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Impel Pharmaceuticals Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| IBSA Pharma Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
How this compares
$10,002 in reported general payments places this provider in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $62,287 |
| FarxigaDapagliflozin Propanediol | 84 | $59,329 |
| JardianceEmpagliflozin | 73 | $59,018 |
| OzempicSemaglutide | 28 | $40,714 |
| MounjaroTirzepatide | 37 | $40,202 |
| LinzessLinaclotide | 57 | $36,669 |
| XareltoRivaroxaban | 41 | $32,097 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $26,562 |
| TrulicityDulaglutide | 21 | $22,562 |
| RybelsusSemaglutide | 16 | $21,322 |
| EliquisApixaban | 20 | $15,105 |
| MovantikNaloxegol Oxalate | 31 | $11,902 |
| SynjardyEmpagliflozin/Metformin Hcl | 11 | $6,613 |
| VascepaIcosapent Ethyl | 18 | $6,168 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 140 | $4,276 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $718 | $85,891116 claims |
| Boehringer IngelheimJardiance, Synjardy | $450 | $65,63184 claims |
| Lilly USA, LLCMounjaro, Trulicity | $434 | $62,76558 claims |
| GSKTrelegy Ellipta | $594 | $62,28771 claims |
| Novo NordiskOzempic, Rybelsus | $665 | $62,03744 claims |
| AbbVieLinzess | $1,985 | $36,66957 claims |
| Johnson & JohnsonXarelto | $212 | $32,09741 claims |
| PfizerEliquis | $331 | $15,10520 claims |
| Redhill Biopharma Inc.Movantik | $110 | $11,90231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.
Other nurse practitioner in Pikeville
- Staci TaylorPikeville$11K
- Kendra DrakePikeville$10K
- Rachael BradfordLexington$447K
- Tara MuddLouisville$243K
- Lee HaasLouisville$95K
- Ashley KnableLouisville$86K
- Christina BenningerLouisville$81K
- Courtney BowlingCampbellsville$47K
- Rebecca BraunerLouisville$40K
- Scott SeitzWinchester$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.